The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

In response to the global burden of severe RSV disease among infants, WHO recommends that all countries introduce either the ...

The flu virus is lingering in Arizona and the season has been vicious. Pediatric flu deaths reached the highest level in ...

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...